Wave Life Sciences (WVE) CMO Christopher Wright details option and share holdings

Rhea-AI Filing Summary

Wave Life Sciences Ltd. Chief Medical Officer Christopher I. Wright filed an initial ownership report showing his equity position. He holds options over 300,000 ordinary shares at an exercise price of $5.94 expiring on May 27, 2035 and options over 273,750 ordinary shares at $12.75 expiring on February 5, 2036, all held directly. He also directly owns 45,625 ordinary shares. Footnotes explain that these options and restricted share units vest in stages between May 27, 2026 and February 8, 2030, contingent on his continued service with the company.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Wright Christopher I

Role Chief Medical Officer

Type	Security	Shares	Price	Value
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Share Option (Right to Buy) — 300,000 shares (Direct); Ordinary Shares — 45,625 shares (Direct)

Footnotes (1)

1. Consists of restricted share units (RSUs). Each RSU represent the right to receive one ordinary share upon vesting. The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030, subject to the Reporting Person's continued service through the applicable vesting date. The option vests as to 25% of the shares on May 27, 2026, and vests as to an additional 6.25% of the shares quarterly thereafter until May 27, 2029, subject to the Reporting Person's continued service through the applicable vesting date. The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030, subject to the Reporting Person's continued service through the applicable vesting date.

Key Figures

Option underlying shares: 300,000 shares Option exercise price: $5.94/share Second option underlying shares: 273,750 shares +4 more

7 metrics

Option underlying shares 300,000 shares Share option at $5.94 exercise price, expiring May 27, 2035

Option exercise price $5.94/share Share option over 300,000 ordinary shares

Second option underlying shares 273,750 shares Share option at $12.75 exercise price, expiring February 5, 2036

Second option exercise price $12.75/share Share option over 273,750 ordinary shares

Direct ordinary shares 45,625 shares Ordinary shares held directly following the reported holdings

Option vesting start 25% on May 27, 2026 Vesting schedule for $5.94 options, then 6.25% quarterly until May 27, 2029

Second option vesting start 25% on February 8, 2027 Vesting schedule for $12.75 options, then 6.25% quarterly until February 8, 2030

Key Terms

restricted share units, RSUs, vest, exercise price, +1 more

5 terms

restricted share units financial

"Consists of restricted share units (RSUs). Each RSU represent the right to receive one ordinary share upon vesting."

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

RSUs financial

"Consists of restricted share units (RSUs). Each RSU represent the right to receive one ordinary share upon vesting."

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

vest financial

"The option vests as to 25% of the shares on May 27, 2026, and vests as to an additional 6.25% of the shares quarterly thereafter"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

exercise price financial

"conversion_or_exercise_price: "5.9400" and "12.7500" for the share options"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

ordinary shares financial

"underlying_security_title: "Ordinary Shares" for the share options and held shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Wright Christopher I

(Last) (First) (Middle)

C/O WAVE LIFE SCIENCES LTD.,

733 CONCORD AVE.

(Street)

CAMBRIDGE MASSACHUSETTS 02138

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/09/2026

3. Issuer Name and Ticker or Trading Symbol
Wave Life Sciences Ltd. [ WVE ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	45,625(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	(2)	05/27/2035	Ordinary Shares	300,000	$5.94	D
Share Option (Right to Buy)	(3)	02/05/2036	Ordinary Shares	273,750	$12.75	D

Explanation of Responses:

1. Consists of restricted share units (RSUs). Each RSU represent the right to receive one ordinary share upon vesting. The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030, subject to the Reporting Person's continued service through the applicable vesting date.

2. The option vests as to 25% of the shares on May 27, 2026, and vests as to an additional 6.25% of the shares quarterly thereafter until May 27, 2029, subject to the Reporting Person's continued service through the applicable vesting date.

3. The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030, subject to the Reporting Person's continued service through the applicable vesting date.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Christopher I. Wright	04/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Christopher Wright report owning in Wave Life Sciences (WVE)?

Christopher Wright reports direct ownership of 45,625 ordinary shares and two large option positions covering 300,000 and 273,750 ordinary shares. These positions represent his equity stake as Chief Medical Officer, combining current share ownership with substantial future purchase rights.

What are the exercise prices of Christopher Wright’s Wave Life Sciences (WVE) options?

He holds options over 300,000 ordinary shares at an exercise price of $5.94 and options over 273,750 ordinary shares at $12.75. These prices define the cost per share he must pay if he chooses to exercise the options in the future.

When do Christopher Wright’s Wave Life Sciences (WVE) options expire?

His $5.94 exercise price options expire on May 27, 2035, and his $12.75 options expire on February 5, 2036. These long-dated expirations give him many years to meet vesting conditions and decide whether to exercise his rights.

How do Christopher Wright’s Wave Life Sciences (WVE) equity awards vest over time?

The footnotes state his options generally vest 25% on a specified first anniversary date, then 6.25% quarterly until fully vested. Related RSUs vest in four equal annual installments from February 8, 2027 through February 8, 2030, subject to continued service.

Does this Wave Life Sciences (WVE) Form 3 show any insider buying or selling?

The Form 3 lists Christopher Wright’s existing holdings and option grants but does not report any explicit purchases or sales. It functions as an initial ownership snapshot rather than a record of new market transactions in Wave Life Sciences shares.